116 related articles for article (PubMed ID: 36484409)
1. Postoperative Metabolic Phenoreversion in Clear Cell Renal Cell Carcinoma.
Manzi M; Zabalegui N; Monge ME
J Proteome Res; 2023 Jan; 22(1):1-15. PubMed ID: 36484409
[TBL] [Abstract][Full Text] [Related]
2. Coupled Mass-Spectrometry-Based Lipidomics Machine Learning Approach for Early Detection of Clear Cell Renal Cell Carcinoma.
Manzi M; Palazzo M; Knott ME; Beauseroy P; Yankilevich P; Giménez MI; Monge ME
J Proteome Res; 2021 Jan; 20(1):841-857. PubMed ID: 33207877
[TBL] [Abstract][Full Text] [Related]
3. Revealing potential lipid biomarkers in clear cell renal cell carcinoma using targeted quantitative lipidomics.
Li W; Wang X; Zhang X; Gong P; Ding D; Wang N; Wang Z
Lipids Health Dis; 2021 Nov; 20(1):160. PubMed ID: 34774030
[TBL] [Abstract][Full Text] [Related]
4. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
5. Lysophosphatidylcholine acyltransferase 1 upregulation and concomitant phospholipid alterations in clear cell renal cell carcinoma.
Du Y; Wang Q; Zhang X; Wang X; Qin C; Sheng Z; Yin H; Jiang C; Li J; Xu T
J Exp Clin Cancer Res; 2017 May; 36(1):66. PubMed ID: 28494778
[TBL] [Abstract][Full Text] [Related]
6. Low level of isocitrate dehydrogenase 1 predicts unfavorable postoperative outcomes in patients with clear cell renal cell carcinoma.
Laba P; Wang J; Zhang J
BMC Cancer; 2018 Aug; 18(1):852. PubMed ID: 30153799
[TBL] [Abstract][Full Text] [Related]
7. Metabolic Footprinting of a Clear Cell Renal Cell Carcinoma in Vitro Model for Human Kidney Cancer Detection.
Knott ME; Manzi M; Zabalegui N; Salazar MO; Puricelli LI; Monge ME
J Proteome Res; 2018 Nov; 17(11):3877-3888. PubMed ID: 30260228
[TBL] [Abstract][Full Text] [Related]
8. miR-144-3p as a novel plasma diagnostic biomarker for clear cell renal cell carcinoma.
Lou N; Ruan AM; Qiu B; Bao L; Xu YC; Zhao Y; Sun RL; Zhang ST; Xu GH; Ruan HL; Yuan CF; Han WW; Shi HC; Yang HM; Zhang XP
Urol Oncol; 2017 Jan; 35(1):36.e7-36.e14. PubMed ID: 27633984
[TBL] [Abstract][Full Text] [Related]
9. Serum miR-122-5p and miR-206 expression: non-invasive prognostic biomarkers for renal cell carcinoma.
Heinemann FG; Tolkach Y; Deng M; Schmidt D; Perner S; Kristiansen G; Müller SC; Ellinger J
Clin Epigenetics; 2018; 10():11. PubMed ID: 29410711
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-15a tissue expression is a prognostic marker for survival in patients with clear cell renal cell carcinoma.
Mytsyk Y; Borys Y; Tumanovska L; Stroy D; Kucher A; Gazdikova K; Rodrigo L; Kruzliak P; Prosecky R; Urdzik P; Dosenko V
Clin Exp Med; 2019 Nov; 19(4):515-524. PubMed ID: 31440867
[TBL] [Abstract][Full Text] [Related]
11. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of interleukin-8 is an independent indicator of poor prognosis in clear-cell renal cell carcinoma.
An H; Zhu Y; Xie H; Liu Y; Liu W; Fu Q; Ye D; Xu J
Tumour Biol; 2016 Apr; 37(4):4523-9. PubMed ID: 26503211
[TBL] [Abstract][Full Text] [Related]
13. Decreased expression of CTR2 predicts poor prognosis of patients with clear cell renal cell carcinoma.
Xia Y; Liu L; Long Q; Bai Q; Wang J; Xu J; Guo J
Urol Oncol; 2016 Jan; 34(1):5.e1-9. PubMed ID: 26411550
[TBL] [Abstract][Full Text] [Related]
14. Elevated tumor-to-liver standardized uptake value ratio (TLR) from preoperative
Wu C; Cui Y; Zhao Y; Chen X; Liao X; Di L; Yin L; Liu M; Wang R
Eur J Radiol; 2020 Oct; 131():109218. PubMed ID: 32882538
[TBL] [Abstract][Full Text] [Related]
15. Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinoma.
Tschirdewahn S; Panic A; Püllen L; Harke NN; Hadaschik B; Riesz P; Horváth A; Szalontai J; Nyirády P; Baba HA; Reis H; Szarvas T
Int J Cancer; 2019 Jul; 145(2):531-539. PubMed ID: 30650187
[TBL] [Abstract][Full Text] [Related]
16. Low Expression of ATM Indicates a Poor Prognosis in Clear Cell Renal Cell Carcinoma.
Ren W; Xue B; Chen M; Liu L; Zu X
Clin Genitourin Cancer; 2019 Jun; 17(3):e433-e439. PubMed ID: 30773312
[TBL] [Abstract][Full Text] [Related]
17. High expression levels of DEF6 predicts a poor prognosis for patients with clear cell renal cell carcinoma.
Zhu ZP; Lin LR; Lv TD; Xu CR; Cai TY; Lin J
Oncol Rep; 2020 Nov; 44(5):2056-2066. PubMed ID: 33000227
[TBL] [Abstract][Full Text] [Related]
18. High Expression of Colony-Stimulating Factor 1 Receptor Associates with Unfavorable Cancer-Specific Survival of Patients with Clear Cell Renal Cell Carcinoma.
Yang L; Liu Y; An H; Chang Y; Zhang W; Zhu Y; Xu L; Xu J
Ann Surg Oncol; 2016 Mar; 23(3):1044-52. PubMed ID: 26467457
[TBL] [Abstract][Full Text] [Related]
19. High expression of Mucin13 associates with grimmer postoperative prognosis of patients with non-metastatic clear-cell renal cell carcinoma.
Xu Z; Liu Y; Yang Y; Wang J; Zhang G; Liu Z; Fu H; Wang Z; Liu H; Xu J
Oncotarget; 2017 Jan; 8(5):7548-7558. PubMed ID: 27911274
[TBL] [Abstract][Full Text] [Related]
20. CCL2/CCR2 axis is associated with postoperative survival and recurrence of patients with non-metastatic clear-cell renal cell carcinoma.
Wang Z; Xie H; Zhou L; Liu Z; Fu H; Zhu Y; Xu L; Xu J
Oncotarget; 2016 Aug; 7(32):51525-51534. PubMed ID: 27409666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
